Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

UK's NICE Backs Novartis Eye Drug, Reversing Earlier Guidance

share with twitter share with LinkedIn share with facebook
share via e-mail
10/05/2012 | 01:16am CEST

By Marta Falconi

ZURICH--The U.K.'s health costs watchdog has reversed earlier guidance and now recommends eye drug Lucentis for a new use, after its maker Novartis AG (>> Novartis AG) offered a better price.

The U.K's National Institute for Health and Clinical Excellence, or NICE, recommends the drug for certain patients who suffer from visual impairment caused by diabetic macular oedema, the regulator said Friday. Without discount, Lucentis costs 742.17 pounds ($1,195) per injection and is given monthly, NICE said.

The new draft guidance is now up for consultation.

NICE decides if particular treatments should be used on the state-run National Health Service. The watchdog had previously rejected Lucentis for diabetic macular oedema, a condition caused by fluid collecting in the central part of the retina, which leads to blurred central vision and other problems.

The drug is already recommended to treat wet age-related macular degeneration.

Novartis said it was pleased with NICE's decision, but lamented the watchdog's move to restrict Lucentis to only those patients with more thickened retinas.

"This has undervalued the benefits that Lucentis provides to all patients with visual impairment due to diabetic macular oedema," the company said.

The Swiss company said it will continue to work with NICE and other health authorities until final draft guidance is issued by early 2013.

Lucentis, which generated nearly 2.05 billion Swiss francs ($2.19 billion) in sales in 2011, was co-developed by Novartis and Swiss rival Roche Holding AG (ROG.VX). Novartis markets the medicine outside the U.S.

Write to Marta Falconi at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Novartis AG
Stocks mentioned in the article
ChangeLast1st jan.
NOVARTIS -1.55% 76.08 Delayed Quote.-7.67%
ROCHE HOLDING LTD. -0.39% 215.65 Delayed Quote.-12.17%
ROCHE HOLDING LTD. -0.35% 179.9 Delayed Quote.-14.69%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on NOVARTIS
04/20Generics group Alvogen puts Eastern European operations up for sale - sources
04/20NOVARTIS : renews commitment to malaria elimination, investing USD 100 million t..
04/20AVEXIS : Novartis tender offer for AveXis commences
04/20AMGEN : Novartis presents first-of-its-kind evidence at AAN reinforcing robust a..
04/20NOVARTIS : Jay Bradner bemoans `redundant investment in the biotech sector` for ..
04/20NOVARTIS : Surface slips in first trading day
04/20NOVARTIS : New Novartis analyses at AAN show siponimod's efficacy on disability ..
04/19NOVARTIS : Patent Issued for Brake System (USPTO 9939603)
04/19NOVARTIS : Patent Issued for Adjusting Laser Treatment in Response to Changes in..
04/19NOVARTIS : Sandoz signs agreement with Pear Therapeutics to develop and commerci..
More news
News from SeekingAlpha
04/20WALL STREET BREAKFAST, APRIL 20TH : Tough Trade Talk With China And Canada, Russ.. 
04/20YOUR DAILY PHARMA SCOOP : Adamas Update, Shire Bidding War, Novartis Results 
04/20WALL STREET BREAKFAST : Spring Meetings For IMF, World Bank 
04/19Novartis AG (NVS) Q1 2018 Results - Earnings Call Transcript 
04/19Novartis AG 2018 Q1 - Results - Earnings Call Slides 
Financials ($)
Sales 2018 52 460 M
EBIT 2018 12 808 M
Net income 2018 9 186 M
Debt 2018 14 590 M
Yield 2018 3,82%
P/E ratio 2018 16,25
P/E ratio 2019 19,04
EV / Sales 2018 4,19x
EV / Sales 2019 4,02x
Capitalization 205 B
Duration : Period :
Novartis Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 92,3 $
Spread / Average Target 18%
EPS Revisions
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
Srikant Madhav Datar Independent Non-Executive Director
Andreas von Planta Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS-7.67%204 972
JOHNSON & JOHNSON-8.71%339 783
PFIZER1.13%217 897
ROCHE HOLDING LTD.-12.17%191 890
AMGEN-0.56%114 648